5q Deletions in MDS and MPN: The Accompanying Molecular Mutations Determine the Phenotype but TP53 Is Frequently Mutated in All Entities: MPN, MDS and MPN/MDS Overlap

被引：0
|
作者：
Haferlach, Claudia [1 ]
Meggendorfer, Manja [1 ]
Schnittger, Susanne [1 ]
Zenger, Melanie [1 ]
Kern, Wolfgang [1 ]
Haferlach, Torsten [1 ]
机构：
[1] MLL Munich Leukemia Lab, Munich, Germany
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 31 条
  • [1] Molecular Analyses of MDS/MPN Overlap Entities According to WHO Classification Reveal a Distinct Molecular Pattern for MDS/MPN, Unclassifiable
    Meggendorfer, Manja
    Haferlach, Torsten
    Jeromin, Sabine
    Haferlach, Claudia
    Kern, Wolfgang
    Schnittger, Susanne
    BLOOD, 2014, 124 (21)
  • [2] THE PROGNOSTIC SIGNIFICANCE OF TP53 MUTATIONS IN MDS PATIENTS WITH DEL(5Q)
    Belickova, M.
    Vesela, J.
    Jonasova, A.
    Planetova, B.
    Valka, J.
    Mikulenkova, D.
    Zemanova, Z.
    Brezinova, J.
    Michalova, K.
    Cermak, J.
    LEUKEMIA RESEARCH, 2015, 39 : S22 - S23
  • [3] THE DEL(5Q) SIZE IN MDS IS CORRELATED TO KARYOTYPE COMPLEXITY AND FREQUENCY OF TP53 MUTATIONS
    Zemanova, Z.
    Brezinova, J.
    Svobodova, K.
    Lhotska, H.
    Aghova, T.
    Vidlakova, D.
    Izakova, S.
    Lizcova, L.
    Ransdorfova, S.
    Mendlikova, I.
    Pavlistova, L.
    Belickova, M.
    Vesela, J.
    Siskova, M.
    Neuwirtova, R.
    Cermak, J.
    Stopka, T.
    Jonasova, A.
    LEUKEMIA RESEARCH, 2021, 108 : S31 - S31
  • [4] TP53 mutations in low-risk MDS patients with isolated del(5q)
    Belickova, M.
    Vesela, J.
    Cermak, J.
    Dostalova, M. M.
    Krejcik, Z.
    Stara, E.
    Zemanova, Z.
    Jonasova, A.
    LEUKEMIA RESEARCH, 2013, 37 : S27 - S28
  • [5] RARE MDS/MPN OVERLAP: WHEN JAK2 V617F MEETS DEL(5Q) MUTATION
    Rupoli, S.
    Morsia, E.
    Goteri, G.
    Capelli, D.
    Scortechini, A. R.
    Poloni, A.
    Micucci, G.
    Garvey, K. B.
    Ceglie, S.
    Fiorentini, A.
    Angelini, M.
    Mancini, S.
    Discepoli, G.
    Viola, N.
    Olivieri, A.
    HAEMATOLOGICA, 2019, 104 : 170 - 170
  • [6] INITIALLY AND NEWLY ACQUIRED TP53 MUTATIONS IN PATIENTS WITH MDS WITH DEL(5Q) WITH/WITHOUT LENALIDOMIDE
    Ganster, C.
    Eder, L.
    Rittscher, K.
    Brzuszkiewicz, E.
    Braulke, F.
    Glass, B.
    Elmaagacli, A.
    Mazzeo, P.
    Shirneshan, K.
    Haase, D.
    LEUKEMIA RESEARCH, 2023, 128
  • [7] Deletions of 5q Promote Genome Instability in TP53-Mutant MDS/AML
    Reilly, Andreea
    Busch, Stephanie
    Abkowitz, Janis L.
    Becker, Pamela S.
    Doulatov, Sergei
    BLOOD, 2019, 134
  • [8] TP53 Mutated del(5q) Myelodysplastic Syndromes (MDS) Patients Have Survivals Comparable to Those with TP53 Wild-Type
    Chan, Onyee
    Al Ali, Najla
    Sallman, David
    Padron, Eric
    Lancet, Jeffrey
    Komrokji, Rami
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S324 - S324
  • [9] TP53 Gene allelic State in Myelodysplastic Syndromes (MDS) with Isolated 5q Deletion
    Montoro, Julia
    Palomo, Laura
    Haferlach, Claudia
    Acha, Pamela
    Chan, Onyee
    Navarro Garces, Victor
    Kubota, Yasuo
    Schulz, Felicitas
    Meggendorfer, Manja
    Briski, Robert
    Al Ali, Najla H.
    Xicoy, Blanca
    Lopez, Felix
    Vidal, Pablo
    Bosch, Francesc
    Gonzalez, Teresa
    Eder, Lea Naomi
    Jerez, Andres
    Tien, Hwei-Fang
    Santini, Valeria
    Bernal Del Castillo, Teresa
    Such, Esperanza
    Wang, Yu-Hung
    Kubasch, Anne Sophie
    Platzbecker, Uwe
    Haase, Detlef
    Diez-Campelo, Maria
    Della Porta, Matteo Giovanni
    Garcia-Manero, Guillermo
    Wiseman, Daniel H.
    Germing, Ulrich
    Maciejewski, Jaroslaw P.
    Komrokji, Rami S.
    Sole, Francesc
    Haferlach, Torsten
    Valcarcel, David
    BLOOD, 2023, 142
  • [10] The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases
    A Stengel
    W Kern
    T Haferlach
    M Meggendorfer
    A Fasan
    C Haferlach
    Leukemia, 2017, 31 : 705 - 711
1234